Outpatient treatment of confirmed COVID-19: a living, rapid review for the American College of Physicians
I Sommer, A Dobrescu, D Ledinger, I Moser… - Annals of internal …, 2023 - acpjournals.org
An updated version of this article was published on 19 September 2023. This article has
been corrected. The original version of the article and supplement (PDF) is appended to this …
been corrected. The original version of the article and supplement (PDF) is appended to this …
Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice
The coronavirus disease 2019 (COVID-19) pandemic remains uncontrolled despite the
rapid rollout of safe and effective severe acute respiratory syndrome coronavirus 2 (SARS …
rapid rollout of safe and effective severe acute respiratory syndrome coronavirus 2 (SARS …
Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms
LJ Stevens, AJ Pruijssers, HW Lee… - Science translational …, 2022 - science.org
The nucleoside analog remdesivir (RDV) is a Food and Drug Administration–approved
antiviral for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
antiviral for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
Discovery, development, and patent trends on molnupiravir: a prospective oral treatment for COVID-19
The COVID-19 pandemic needs no introduction at present. Only a few treatments are
available for this disease, including remdesivir and favipiravir. Accordingly, the …
available for this disease, including remdesivir and favipiravir. Accordingly, the …
Incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir
Importance Some patients treated with nirmatrelvir-ritonavir have experienced rebound of
COVID-19 infections and symptoms; however, data are scarce on whether viral rebound …
COVID-19 infections and symptoms; however, data are scarce on whether viral rebound …
Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants
SE Greasley, S Noell, O Plotnikova, RA Ferre… - Journal of Biological …, 2022 - ASBMB
The COVID-19 pandemic continues to be a public health threat with emerging variants of
SARS-CoV-2. Nirmatrelvir (PF-07321332) is a reversible, covalent inhibitor targeting the …
SARS-CoV-2. Nirmatrelvir (PF-07321332) is a reversible, covalent inhibitor targeting the …
Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19
Background Molnupiravir is an oral prodrug of β-d-N4-hydroxycytidine, active against SARS-
CoV-2 in vitro and in animal models. We report data from the phase 2 component of MOVe …
CoV-2 in vitro and in animal models. We report data from the phase 2 component of MOVe …
Therapeutics for COVID-19
SS Toussi, JL Hammond, BS Gerstenberger… - Nature …, 2023 - nature.com
Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …
(COVID-19) illness were available within a year of the pandemic being declared but there …
Nirmatrelvir-ritonavir for COVID-19
EG McDonald, TC Lee - Cmaj, 2022 - Can Med Assoc
Nirmatrelvir-ritonavir for COVID-19 | CMAJ Skip to main content Main menu Home Content
Current issue Past issues Early releases Collections Sections Blog Infographics & illustrations …
Current issue Past issues Early releases Collections Sections Blog Infographics & illustrations …